Citius Oncology, Inc. (CTOR) - Total Liabilities
Based on the latest financial reports, Citius Oncology, Inc. (CTOR) has total liabilities worth $65.43 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Citius Oncology, Inc. - Total Liabilities Trend (2022–2025)
This chart illustrates how Citius Oncology, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See CTOR net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Citius Oncology, Inc. Competitors by Total Liabilities
The table below lists competitors of Citius Oncology, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Softtech Engineers Limited
NSE:SOFTTECH
|
India | Rs831.31 Million |
|
Facephi Biometria SA
MC:FACE
|
Spain | €26.22 Million |
|
Drb Industrial
KO:163560
|
Korea | ₩116.34 Billion |
|
Midsummer AB (publ)
ST:MIDS
|
Sweden | Skr313.58 Million |
|
Nordic Resources Ltd
AU:NNL
|
Australia | AU$1.02 Million |
|
Commercial Vehicle Group Inc
NASDAQ:CVGI
|
USA | $263.74 Million |
|
Spruce Ridge Resources Ltd.
V:SHL
|
Canada | CA$449.73K |
|
Choong Ang Vaccine Laboratory Co. Ltd
KQ:072020
|
Korea | ₩17.61 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Citius Oncology, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Citius Oncology, Inc..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Citius Oncology, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Citius Oncology, Inc. (2022–2025)
The table below shows the annual total liabilities of Citius Oncology, Inc. from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $56.08 Million | +46.69% |
| 2024-09-30 | $38.23 Million | +72.21% |
| 2023-09-30 | $22.20 Million | +245.63% |
| 2022-09-30 | $6.42 Million | -- |
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidia… Read more